02/12/2025
SOCRA Members,
With the recent NIH supplemental guidance capping all current and future indirect costs at 15%, we find ourselves in a position of significant uncertainty. As clinical research professionals, we are acutely aware of the severe impact this will have on public health, crippling our ability to conduct vital clinical research across the United States.
Indirect costs fund essential functions necessary to support research. These encompass administrative support, maintenance of research facilities, and compliance functions—core components that form the backbone of our research infrastructure. The cap undermines the ability of institutions to sustain comprehensive research environments, thereby jeopardizing scientific innovation and advancements in medical treatments.
SOCRA remains steadfast in its commitment to our members during these challenging times. We recognize your concerns and understand the far-reaching consequences of this policy change. In response, we are actively collaborating with leaders in the industry to advocate for the vital importance of sustained investment in research infrastructure. Our efforts include engaging with stakeholders across the research industry, as well as partnering with other impacted organizations to ensure that the voices of clinical research professionals are heard and acknowledged.
We commend the dedication and resilience of you, our members, and rest assured, SOCRA will continue to stand by you, leveraging our collective strength to ensure that the critical work of advancing public health through clinical research can continue unabated.
Sincerely,
SOCRA Board of Directors
